Clinical trials: Esophageal Squamous Carcinoma
Esophageal Squamous Cell Carcinoma
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).
- Trial name
- NCT02649361
- Testing
- Anlotinib
- Where
- 18 sites in China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Esophageal Neoplasms, Carcinoma, Squamous Cell
A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma
To determine whether chemotherapy before surgery makes better outcome than chemotherapy after surgery in patients with esophageal squamous cell carcinoma
- Trial name
- NCT00190554
- Testing
- Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2, (Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery
- Where
- 24 sites in Japan
- Volunteers
- 330 people
- Sponsor
- Japan Clinical Oncology Group
Locally Advanced Esophageal Squamous Cell Carcinoma
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities.
- Trial name
- EC-CRT-007 (NCT06187597)
- Testing
- S-1, Toripalimab, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Stage IV Esophageal Squamous Cell Carcinoma
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy.
- Trial name
- NCT02011594
- Testing
- Nimotuzumab
- Where
- 2 sites in China
- Sponsor
- Zhejiang University
Unresectable Esophageal Cancer
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT.
- Trial name
- NCT04005170
- Testing
- Toripalimab, Paclitaxel/Cisplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Mian XI
QL1706, ESCC
Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma.
- Conditions
- QL1706, ESCC, First-line Therapy
- Trial name
- NCT07533305
- Testing
- QL1706 plus nab-paclitaxel and cisplatin
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Bladder Cancer, Squamous Cell Carcinoma of the Lung
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have…
- Conditions
- Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
- Trial name
- NCT07217171
- Testing
- EVOLVE104
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- EvolveImmune United, Inc
Esophageal Squamous Cell Carcinoma, Progression to PD-1 Antibody
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.
- Trial name
- NCT04866381
- Testing
- SHR-6390, SHR-6390 + Camrelizumab (SHR-1210), Camrelizumab (SHR-1210) + SHR-1020
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
This clinical trial is looking at two new vaccines called ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3 and MVA-NYESO given with patients' standard of care treatment (chemotherapy and an immune checkpoint inhibitor).
- Trial name
- NCT04908111
- Testing
- ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment
- Where
- 9 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cancer Research UK
Esophageal Squamous Cell Carcinoma, Esophageal Cancer
Esophageal cAncer Screening Trial
This multicenter study aims to include 15000 participants undergoing screening upper gastrointestinal endoscopy and establish a risk prediction model for esophageal squamous cell carcinoma and esophagogastric junctional (EGJ)…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- EAST (NCT04609813)
- Testing
- Sponge cytological test
- Where
- China
- Volunteers
- 14,597 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Solid Tumors, Metastatic Melanoma
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3)…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT03708328
- Testing
- Lomvastomig
- Where
- 17 sites in United States, Denmark and 4 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Cervical Cancer, Gastric Cancer
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
- Conditions
- Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT03652077
- Testing
- INCAGN02390
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Oropharyngeal Cancer, Dysphagia, Oropharyngeal
Liposomal Bupivacaine and Transoral Robotic Surgery
This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell…
- Conditions
- Oropharyngeal Cancer, Dysphagia, Oropharyngeal, Post Operative Pain, Transoral Robotic Surgery
- Trial name
- NCT05862792
- Testing
- Liposomal bupivacaine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Geisinger Clinic
Oropharynx Cancer, Pain
Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma
To investigate the treatment related effects of transoral robotic surgery (TORS) or oncological treatment of oropharyngeal squamous cell carcinoma with a 1-year follow up.
- Conditions
- Oropharynx Cancer, Pain, Swallowing Disorder, Quality of Life
- Trial name
- NCT03418909
- Testing
- Primary Trans Oral Robotic Surgery (TORS), Radio(chemo)therapy
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oral Cancer
The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer
The human oral cavity is a diverse habitat that contains approximately 700 prokaryotic species. The oral microbiome is comprised of 44% named species, 12% isolates representing unnamed species, and 44% phylotypes known only from…
- Trial name
- NCT03304132
- Testing
- Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach, Classification of Oral Microbiome Using taxonomic approach
- Where
- United States
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Esophageal Squamous Cell Carcinoma
Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy Era
This retrospective real-world cohort study will evaluate the efficacy and safety of different radiotherapy target volume extents in patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07879898
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Squamous Cell Carcinoma of the Esophagus
Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy
This is a multicenter, randomized, controlled, open-label phase II study including patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based…
- Trial name
- RAMOS (NCT03762564)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 2 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.